Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1346)	11/27/2001 2:56:58 AM
From: Icebrg	Respond to of 10345

Elan Pharma Invest Files To Sell 510,825 Bioject Shares Dow Jones Newswires WASHINGTON -- Elan Pharmaceutical Investments Ltd. recently filed to sell 510,825 common shares of Bioject Medical Technologies Inc. (BJCT), according to a Form 144 released Monday by the Securities and Exchange Commission. Elan listed Nov. 23 as the approximate date of sale and valued the shares at $5.3 million. Elan listed Bear Stearns & Co. as broker. In a proxy statement filed Nov. 2 with the SEC, Bioject said Elan held 3.8 million of its common shares, or 29.15% of those outstanding. That total included exercisable warrants to purchase 1.1 million common shares; 692,694 shares of Series A convertible preferred stock, convertible into 1.4 million shares of common stock; and 391,830 shares of Series C convertible preferred stock, convertible into 783,660 shares of common stock. Bioject makes injection systems that deliver medication without the use of a needle. A Form 144 indicates an intention to sell restricted stock, but it isn't a commitment to do so.